Intervet sees 6% global growth

Outpacing market growth, EBIT before incidentals increased 2% to EUR 213 million, resulting in an EBIT margin of 18.9%. Divestments and acquisitions had a negative impact on revenues of 3%.

In Europe, autonomous growth was 5%, while in North America, revenues from ongoing operations grew 12%. At the end of the year, Intervet received important product approvals for Zilmax®, a feed additive for cattle and PreveNile®, a West Nile Virus vaccine for horses.

Sign up for our
regular news updates

Related news items:

•    November Agriculture And Fisheries Council Agenda
•    Potential For Fishmeal-Free Salmon
•    Fish Wholesaling Industry Research
•    College To Boost Fish Farming
•    Consultation On Net And Trap Licences

Related News Categories: Fish Health, Markets and Economics, Company/Products, General

Sign up for our
regular news updates

More Fish Industry News

•   November Agriculture And Fisheries Council Agenda
•   Potential For Fishmeal-Free Salmon
•   Fish Wholesaling Industry Research
•   College To Boost Fish Farming
•   Consultation On Net And Trap Licences
•   Fish farming in Paddy Fields Takes Off
•   Tilapia-Skin Gelatine Next for Aquafinca
•   VIV China Reflects Development of Chinese Industry
•   Protection for Island Cockle Industry
•   Accessing Markets Directly To Improve Payments